Creative Planning
TEVA icon

Creative Planning’s Teva Pharmaceuticals TEVA Stock Holding History

Creative Planning’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Buy
71,019
+6,111
+9% +$204K ﹤0.01% 1937
2026
Q1 		$1.96M Buy
64,908
+2,072
+3% +$66.7K ﹤0.01% 1901
2025
Q4 		$1.96M Buy
62,836
+5,023
+9% +$124K ﹤0.01% 1740
2025
Q3 		$1.17M Buy
57,813
+1,649
+3% +$29K ﹤0.01% 1970
2025
Q2 		$941K Buy
56,164
+10,784
+24% +$174K ﹤0.01% 1911
2025
Q1 		$697K Sell
45,380
-4,660
-9% -$83.2K ﹤0.01% 2005
2024
Q4 		$1.1M Buy
50,040
+7,225
+17% +$131K ﹤0.01% 1576
2024
Q3 		$772K Buy
42,815
+1,863
+5% +$32.6K ﹤0.01% 1733
2024
Q2 		$665K Sell
40,952
-568
-1% -$8.75K ﹤0.01% 1719
2024
Q1 		$586K Sell
41,520
-1,662
-4% -$20.9K ﹤0.01% 1735
2023
Q4 		$451K Sell
43,182
-1,073
-2% -$10K ﹤0.01% 1782
2023
Q3 		$451K Sell
44,255
-31,451
-42% -$293K ﹤0.01% 1631
2023
Q2 		$570K Buy
75,706
+3,465
+5% +$28.1K ﹤0.01% 1468
2023
Q1 		$639K Sell
72,241
-3,722
-5% -$36.8K ﹤0.01% 1328
2022
Q4 		$693K Buy
75,963
+1,759
+2% +$15.3K ﹤0.01% 1238
2022
Q3 		$599K Buy
74,204
+5,941
+9% +$52.5K ﹤0.01% 1217
2022
Q2 		$513K Buy
68,263
+9,408
+16% +$82K ﹤0.01% 1301
2022
Q1 		$553K Sell
58,855
-25,819
-30% -$215K ﹤0.01% 1271
2021
Q4 		$678K Sell
84,674
-3,707
-4% -$33.5K ﹤0.01% 1139
2021
Q3 		$861K Sell
88,381
-29,044
-25% -$272K ﹤0.01% 1021
2021
Q2 		$1.16M Sell
117,425
-53,139
-31% -$562K ﹤0.01% 875
2021
Q1 		$1.97M Buy
170,564
+16,643
+11% +$191K ﹤0.01% 733
2020
Q4 		$1.49M Buy
153,921
+1,090
+0.7% +$10.4K ﹤0.01% 784
2020
Q3 		$1.38M Buy
152,831
+24,665
+19% +$261K ﹤0.01% 690
2020
Q2 		$1.58M Sell
128,166
-113,571
-47% -$1.28M ﹤0.01% 581
2020
Q1 		$2.17M Sell
241,737
-55,337
-19% -$567K 0.01% 408
2019
Q4 		$2.91M Sell
297,074
-65,390
-18% -$584K 0.01% 403
2019
Q3 		$2.49M Buy
362,464
+178,022
+97% +$1.36M 0.01% 434
2019
Q2 		$1.7M Buy
184,442
+65,642
+55% +$792K 0.01% 548
2019
Q1 		$1.86M Buy
118,800
+8,388
+8% +$148K 0.01% 488
2018
Q4 		$1.7M Sell
110,412
-91,032
-45% -$1.87M 0.01% 461
2018
Q3 		$4.34M Buy
201,444
+33,026
+20% +$767K 0.02% 301
2018
Q2 		$4.1M Sell
168,418
-23,271
-12% -$475K 0.02% 303
2018
Q1 		$3.28M Buy
191,689
+14,419
+8% +$282K 0.01% 341
2017
Q4 		$3.36M Sell
177,270
-82,239
-32% -$1.24M 0.01% 328
2017
Q3 		$4.57M Buy
259,509
+138,921
+115% +$3.13M 0.02% 258
2017
Q2 		$4.01M Sell
120,588
-2,459
-2% -$76.1K 0.02% 268
2017
Q1 		$3.95M Buy
123,047
+21,731
+21% +$742K 0.02% 258
2016
Q4 		$3.67M Buy
101,316
+35,613
+54% +$1.42M 0.02% 264
2016
Q3 		$3.02M Buy
65,703
+24,795
+61% +$1.29M 0.02% 290
2016
Q2 		$2.06M Buy
40,908
+3,160
+8% +$168K 0.01% 330
2016
Q1 		$2.02M Buy
37,748
+5,986
+19% +$351K 0.02% 317
2015
Q4 		$2.08M Buy
31,762
+8,608
+37% +$532K 0.02% 301
2015
Q3 		$1.31M Sell
23,154
-1,248
-5% -$80.9K 0.01% 406
2015
Q2 		$1.44M Buy
24,402
+1,267
+5% +$78.2K 0.01% 372
2015
Q1 		$1.44M Sell
23,135
-2,432
-10% -$141K 0.01% 353
2014
Q4 		$1.47M Buy
25,567
+4,357
+21% +$243K 0.02% 341
2014
Q3 		$1.14M Sell
21,210
-768
-3% -$40.7K 0.01% 359
2014
Q2 		$1.15M Buy
21,978
+2,835
+15% +$145K 0.01% 350
2014
Q1 		$1.01M Sell
19,143
-5,699
-23% -$263K 0.02% 367
2013
Q4 		$996K Sell
24,842
-5,176
-17% -$204K 0.02% 305
2013
Q3 		$1.13M Buy
30,018
+3,521
+13% +$137K 0.02% 241
2013
Q2 		$1.04M Buy
+26,497
New +$1.03M 0.02% 221

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Creative Planning's TEVA Position: Q2 2026 in Review

Creative Planning increased its Teva Pharmaceuticals (TEVA) stake by 9.4% in Q2 2026, buying an estimated $204K and bringing the position to 71,019 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

Creative Planning first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.57M in Q3 2017. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Creative Planning held 71,019 shares of Teva Pharmaceuticals worth $2.41M as of Q2 2026.
  • Creative Planning bought 6,111 Teva Pharmaceuticals shares in Q2 2026, an estimated $204K.
  • Teva Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #1937 holding.
  • Creative Planning first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Creative Planning's Teva Pharmaceuticals position peaked at $4.57M in Q3 2017.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.